Alitair gets patent for REA platform; Arrowhead acquires startup Alvos;

> Alitair announced it has received a patent allowance for REA, its ion-exchange resin-delivery platform for oral-solid drugs. Release

> Echo Therapeutics has run an operating loss since its inception, but continued development of its Prelude SkinPrep platform could help the company turn profit. More

> Arrowhead ($ARWR) has purchased the startup Alvos, bringing in the company's drug delivery tech for its RNAi treatments. Story

> Drug delivery firm Intersect ENT is quadrupling its operation size with an expansion in California. It is looking to expand production of Propel, its mometasone furoate implant for chronic sinusitis. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.